1996 Abstracts The American Pediatric Society and The Society for Pediatric Research

Pediatric Research (1996) 39, 250–250; doi:10.1203/00006450-199604001-01509

INTRAVENOUS IBUPROFEN (IBU) FOR THE TREATMENT OF PATENT DUCTUS ARTERIOSUS(PDA) IN PRETERM INFANTS WITH RESPIRATORY DISTRESS SYNDROME (RDS). 1486

Bart Van Overmeire1, Ingrid Follens1, Suzanne Hartmann1, Ludo Mahieu1 and Patrick J Van Reempts1

1Department of Pediatrics, Division of Neonatology, University Hospital of Antwerp, Belgium.

Background: IBU has been used as an alternative cyclo-oxygenase inhibitor for prophylactic treatment of PDA and for the prevention of intraventricular hemorrhages (IVH) in preterm infants.

Aim of the study: To evaluate effectiveness and side effects of IBU in preterm infants with RDS and PDA as compared to indomethacin (INDO) and controls.

Setting: Blind prospective randomized trial in a tertiary referral hospital.

Intervention: 42 infants with RDS and PDA were randomly assigned to receive at day 2-3 IBU (10 mg/kg iv followed by 5 mg/kg iv after 24 and 48 hrs), INDO (3×0.2 mg/kg iv at 12 hrs intervals), or no treatment(control). Patency of the ductus was evaluated by echocardiography at d2-3 and at d8. Follow-up concerned clinical evolution, uresis and cranial ultrasound.

Results: Table


Conclusion: (1) In preterm infants with RDS and PDA, IBU at d2-3, is as effective as INDO in closing PDA and (2) IBU causes less oliguria than INDO.